NasdaqCM:RZLTBiotechs
Rezolute (RZLT) Valuation Revisited After Phase 3 sunRIZE Trial Misses Primary and Key Secondary Endpoints
Rezolute (RZLT) just released topline data from its pivotal Phase 3 sunRIZE trial in congenital hyperinsulinism, and the drug missed both primary and key secondary endpoints, forcing investors to quickly reassess the story.
See our latest analysis for Rezolute.
The setback helps explain why Rezolute’s 30 day share price return sits at around negative 72 percent even after a sharp short term rebound. The share price closed at 2.74 dollars, and while the three year total shareholder return is...